Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.


Biotechnology

Pharmaceutical

Therapeutics

Carbon Biosciences

Carbon Biosciences' headquarters in Lexington, MA, United States

Joel Schneider

Robert M. Kotin

Carolyn Pelletier

Steve Dipalma

Sebastian Aguirre Kozlouski, Ph.D.

Yoshi Hashimoto

Jianming Qiu

Jeff Moffit, PhD, DABT

Beckett Hart

Amy Lurier

Sebastian Aguirre

Jeff Moffit

Bev Davidson

Adrian Thrasher

Chen Schor

Jay Chiorini

David Steinberg

Derek Yoon

John F. Engelhardt

Description

People (7)

Jeff Moffit, PhD, DABT

Yoshi Hashimoto

Carolyn Pelletier

Michael Rak

Alfred G. Tamayo

Sebastian Aguirre Kozlouski, Ph.D.

Samantha Smith

Jobs